NASDAQ:HOTH - Hoth Therapeutics Stock Price, Forecast & News

Hoth Therapeutics trades on the NASDAQ under the ticker symbol "HOTH."

Hoth Therapeutics Inc (NASDAQ:HOTH) posted its earnings results on Tuesday, November, 12th. The company reported ($0.17) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.10) by $0.07. View Hoth Therapeutics' Earnings History.

Hoth Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, April 6th 2020. View Earnings Estimates for Hoth Therapeutics.

2 brokers have issued 12-month price objectives for Hoth Therapeutics' stock. Their forecasts range from $10.00 to $10.00. On average, they anticipate Hoth Therapeutics' stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 99.4% from the stock's current price. View Analyst Price Targets for Hoth Therapeutics.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hoth Therapeutics in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Hoth Therapeutics.

Media stories about HOTH stock have been trending extremely negative recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Hoth Therapeutics earned a coverage optimism score of -4.0 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Hoth Therapeutics.

Hoth Therapeutics saw a drop in short interest in December. As of December 31st, there was short interest totalling 38,300 shares, a drop of 11.3% from the December 15th total of 43,200 shares. Based on an average trading volume of 26,100 shares, the days-to-cover ratio is presently 1.5 days. Currently, 0.9% of the shares of the stock are short sold. View Hoth Therapeutics' Current Options Chain.

Some companies that are related to Hoth Therapeutics include Athersys (ATHX), Protagonist Therapeutics (PTGX), Bicycle Therapeutics (BCYC), Five Prime Therapeutics (FPRX), Arbutus Biopharma (ABUS), Ovid Therapeutics (OVID), Nature's Sunshine Products (NATR), Aravive (ARAV), Monopar Therapeutics (MNPR), NuCana (NCNA), Fortress Biotech (FBIO), Arcturus Therapeutics (ARCT), Harrow Health (HROW), Mustang Bio (MBIO) and Aldeyra Therapeutics (ALDX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Hoth Therapeutics investors own include Verizon Communications (VZ), General Motors (GM), Pfizer (PFE), NovaBay Pharmaceuticals (NBY), Cronos Group (CRON), Ekso Bionics (EKSO), Genocea Biosciences (GNCA), Huntington Bancshares (HBAN), Inseego (INSG) and Sesen Bio (SESN).

(HOTH) raised $8 million in an IPO on Friday, February 15th 2019. The company issued 1,300,000 shares at $5.50-$6.50 per share. Laidlaw & Company (UK) Ltd. served as the underwriter for the IPO.

Shares of HOTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of HOTH stock can currently be purchased for approximately $5.01.

Hoth Therapeutics has a market capitalization of $50.74 million. The company earns $-2,500,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis. Hoth Therapeutics employs 2 workers across the globe.View Additional Information About Hoth Therapeutics.

The official website for Hoth Therapeutics is http://www.hoththerapeutics.com/.

Hoth Therapeutics' mailing address is 1 Rockefeller Plaza Suite 1039, New York NY, 10020. The company can be reached via phone at 646-756-2997 or via email at [email protected]